What is HC Wainwright’s Estimate for BNTC Q2 Earnings?

Benitec Biopharma Limited (NASDAQ:BNTC) – Research analysts at HC Wainwright issued their Q2 2026 EPS estimates for Benitec Biopharma in a research report issued to clients and investors on Monday, November 24th. HC Wainwright analyst R. Selvaraju forecasts that the biotechnology company will post earnings per share of ($0.24) for the quarter. HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q3 2026 earnings at ($0.27) EPS and Q4 2026 earnings at ($0.29) EPS.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.13.

BNTC has been the topic of a number of other research reports. Wall Street Zen upgraded Benitec Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. JMP Securities set a $22.00 price objective on Benitec Biopharma in a research report on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Benitec Biopharma in a report on Wednesday, October 8th. Citizens Jmp boosted their target price on shares of Benitec Biopharma from $20.00 to $22.00 and gave the company a “market outperform” rating in a research report on Tuesday, November 4th. Finally, Oppenheimer restated an “outperform” rating and issued a $29.00 price target (down from $35.00) on shares of Benitec Biopharma in a research note on Tuesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $25.33.

Benitec Biopharma Trading Up 0.7%

Shares of Benitec Biopharma stock opened at $13.02 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 54.67 and a quick ratio of 54.67. The business has a fifty day simple moving average of $14.36 and a two-hundred day simple moving average of $13.70. Benitec Biopharma has a 1 year low of $9.49 and a 1 year high of $17.15. The company has a market capitalization of $440.88 million, a price-to-earnings ratio of -8.86 and a beta of 0.23.

Insider Activity at Benitec Biopharma

In related news, Director Suvretta Capital Management, L acquired 1,481,481 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The shares were bought at an average cost of $13.50 per share, with a total value of $19,999,993.50. Following the completion of the purchase, the director directly owned 9,538,175 shares in the company, valued at $128,765,362.50. The trade was a 18.39% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its stake in Benitec Biopharma by 44.5% in the third quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 904 shares during the period. MYDA Advisors LLC grew its position in Benitec Biopharma by 4.0% in the 1st quarter. MYDA Advisors LLC now owns 52,000 shares of the biotechnology company’s stock valued at $677,000 after purchasing an additional 2,000 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new stake in Benitec Biopharma during the 2nd quarter valued at $38,000. Russell Investments Group Ltd. acquired a new position in Benitec Biopharma during the third quarter worth $79,000. Finally, Bank of America Corp DE lifted its stake in shares of Benitec Biopharma by 2,255.8% in the second quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 6,587 shares in the last quarter. 52.19% of the stock is owned by institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.